Skip to content

Back to all articles

Finding Lung Cancer Earlier: Why Screening and Incidental Detection Both Matter

03 February 2026
Finding Lung Cancer Earlier: Why Screening and Incidental Detection Both Matter

In this post

Finding Lung Cancer Earlier: Why Screening and Incidental Detection Both Matter
4:33

Lung cancer patients in the US are typically diagnosed through one of two pathways: lung cancer screening or incidentally (i.e., suspicious lung nodule is found on a scan done primarily for another concern).

Early detection and diagnosis change the course of lung cancer, and it matters on both pathways.

Screening programs (planned, proactive detection)

Lung cancer screening is built for people at higher risk and is designed to find cancer before symptoms appear. The current United States Preventive Services Taskforce (USPSTF) recommendation is an annual low-dose CT (LDCT) for adults ages 50 to 80 who have a 20 pack-year smoking history and currently smoke or who have quit within the past 15 years. Screening is generally stopped once someone has not smoked for 15 years or develops a health problem that limits life expectancy or ability to have curative lung surgery. 1

For Medicare patients specifically, lung cancer screening is covered for people ages 50 to 77, with the same pack-year and quit-within-15-years criteria, and no current symptoms. 2

Screening saves lives, but it is not perfect. The real-world “cost” of screening can include:

  • False positives that lead to extra imaging and sometimes invasive procedures 3
  • Overdiagnosis, where some detected cancers might never have caused harm in a person’s lifetime 3
  • Incidental findings and anxiety while waiting for follow-up 4

That is why high-quality screening programs do more than schedule a scan. They standardize how nodules are assessed and followed, and they’re built on shared decision-making, so patients understand both benefits and trade-offs. 1

Incidental detection programs (unplanned findings that still need a plan)

The second, often larger pathway comes from “incidental” nodules, that is nodules found on CT scans done for other reasons (e.g., ED chest pain workups, trauma scans, cardiac CT, pre-op imaging, and more). These patients are not coming through a screening pathway, but in the US each year, 1.5 million lung nodules are found and documented in radiology reports. 5

This is where programs succeed or fail. Robust incidental lung nodule programs focus on making sure that:

  • Nodules are captured reliably and centrally, not buried in narrative text
  • Findings are communicated clearly to the right clinician and to the patient
  • Follow-up is tracked, so if a patient is scheduled for a follow-up CT in 6 to 12 months, that scan occurs
  • Risk is stratified consistently, so patients with benign nodules are not over-treated, while patients with high-risk nodules receive timely care

When incidental nodules fall through the cracks, people can lose months or years. When they are managed well, patients and physicians receive timely and actionable information to make the best decision.

Why we need both pathways

Screening programs help the right high-risk patients get scanned on purpose, with payer-covered eligibility rules in the US. 1

Incidental detection programs ensure that everyone else who already had imaging is not missed because follow-up was unclear, inconsistent, or lost to referral.

Early detection is not a single program. It is a coordinated system of screening plus incidental nodule management, built to find cancer earlier while minimizing unnecessary testing.

References:

    1. Lung cancer: screening. (2021, March 9) https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening

    1. Lung cancer screenings. (n.d.). Medicare. https://www.medicare.gov/coverage/lung-cancer-screenings

    1. Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971–987. doi:10.1001/jama.2021.0377

    1. Pinsky PF. Assessing the benefits and harms of low-dose computed tomography screening for lung cancer. Lung Cancer Manag. 2014;3(6):491-498. doi: 10.2217/LMT.14.41. PMID: 26617677; PMCID: PMC4662564.

    1. Incidental Pulmonary Nodule Detection and Factors Influencing Follow-Up Pannu, Jasleen K. et al. CHEST Pulmonary, Volume 0, Issue 0, 100187